This pharmaphorum podcast explores how AI is transforming drug development and commercialization, with Norstella Chief Product Officer Kris Kaneta discussing the growing role of clinical AI powered by robust patient-level
Drug development has made huge scientific progress over the last decade. The way we run clinical development has changed far less. Timelines are still long. Costs are still high. And
For GLP-1 therapies, traditional data sources alone aren’t enough to understand the full patient journey. NorstellaLinQ’s 74 billion data points give you the full picture and help you optimize GLP-1
Norstella recently spoke with the Wall Street Journal’s Brian Gormley in a feature article: Biotech VC’s Vaccine Die-Hards. The piece explores how investment has pivoted away from vaccines, leaving a
Rare Disease Day will be commemorated on 28 February this year, as it has been every year since 2008. Coordinated by EURORDIS-Rare Diseases Europe, the day will bring together over
In the first few weeks following the launch of oral semaglutide, early prescription activity answered a familiar question: Uptake was
The Norstella Panel puts you in the room with the people who decide. Active P&T leaders. Payer and PBM decision
As real-world data (RWD) evolves, the rise of unstructured data—from clinical notes to lab reports—is transforming how life sciences teams
Real-world data (RWD) and Artificial Intelligence (AI) are evolving fast, and with the integration of unstructured data, large language models
The Norstella Real-World Data Executive Forum explores how real-world data (RWD) can accelerate treatment progress in neuro-oncology, particularly for small
Innovation at Norstella often begins with a question: What if we could move faster—without sacrificing quality or compliance? During a